FAQs: MAD7 commercial terms

Can I really use MAD7 for free?

Yes! Inscripta is providing the DNA sequence of E. coli codon-optimized MAD7 free for any academic or commercial R&D use. A license is provided when the sequence is downloaded, although if requested, Inscripta can provide a hard copy license for free use of MAD7 in research.

The issued patent claims to the use of MAD7 include the use of specific guide RNAs.   Are these also free for use with MAD7?

Yes – the free license for the use of MAD7 includes a free license for any guide RNAs that may be used with MAD7.  There really isn’t a catch here!

What if I generate an edited cell line and launch this as a commercially available product? Is it still free?

MAD7 is free for all research and development. For generating edited cell lines, where the edit is contained within the cells but not the MAD7 nuclease, this is still free and there is no commercial reach-through. A license, with a single-digit royalty, is needed if you are selling the enzyme or if you are selling a product that contains the actual enzyme. A license is provided when the sequence is downloaded, although if requested, Inscripta can provide a hard copy license for free use of MAD7 in research at your institution.

How free is MAD7? What’s the fine print?

MAD7 is free for all commercial or academic research with no reach-through royalties or costs! Inscripta is truly committed to get MAD7 into the hands of researchers to enable CRISPR-based genome engineering. Please refer to the Terms & Conditions (inscripta.com/madzymes) for additional details.

Why is MAD7 free to researchers?

Inscripta wants to enable researchers to perform CRISPR-based gene editing without the complication of negotiating and acquiring an expensive license. We want to ensure your research is a success and that you own your research!

How can I be sure my use in commercial research and development will not be subject to a future royalty?

Inscripta is committed to providing the MAD7 sequence for all R&D use without reach-through royalty rights, which means any use of the enzyme in the development of a commercial product will not result in a royalty to Inscripta for making, using or selling the developed commercial product. The only time a royalty will attach to the use of MAD7 is for a manufacturing process that uses MAD7 on an ongoing basis or a product that physically contains MAD7 or a related enzyme covered by Inscripta IP. Specific Terms & Conditions of the use of this enzyme can be found at inscripta.com/madzymes.